Abstract
The early assessment of new symptomatic drugs against Alzheimer’s disease remains difficult because of the lack of a predictive end-point. The use of a battery including different parameters could improve this early development. In order to test the reverse effect of symptomatic drugs in healthy volunteers, scientists have developed new experimental paradigms to artificially induce transient cognitive impairments in healthy volunteers akin to those observed in Alzheimer’s disease, i.e. Cognitive Challenge Models. In this context, transient hypoxia could be a relevant Cognitive Challenge Model. The deleterious effects of hypoxia on cognition, as described in the literature, should be considered carefully since they are usually assessed with different populations that do not have the same hypoxic sensitivity. Hypoxia can be obtained by the means of two different methods: normobaric and hypobaric hypoxia. In both designs, cognitive changes can be directly modulated by the severity of hypoxic levels. The purpose of this review is to gather existing support on the application of hypoxia within different cognitive domains and to highlight the scientific interests of such a model to predict and select promising drug candidates. We aimed at reviewing in detail the methods, designs and cognitive paradigms used in non-pharmacological hypoxia studies. Probing the four main cognitive functions will allow identifying the extent to which different hypoxia designs selectively compromise cognitive functioning. For each cognitive process, the convergent and divergent results are discussed in terms of paradigm differences whereas we will focus on defining the optimal methodology for obtaining the desired effects.
Keywords: Alzheimer disease, clinical trial, cognition, cognitive challenge model, compensatory mechanism, healthy volunteers, hypoxia.
CNS & Neurological Disorders - Drug Targets
Title:Neurobehavioral and Cognitive Changes Induced by Hypoxia in Healthy Volunteers
Volume: 15 Issue: 7
Author(s): Laura Lanteaume, Catherine Cassé-Perrot, Marie-Noëlle Lefebvre, Christine Audebert, Julie Deguil, Alexandra Auffret, Lisa Otten, David Bartrés-Faz, Olivier Blin, Régis Bordet and Joëlle Micallef
Affiliation:
Keywords: Alzheimer disease, clinical trial, cognition, cognitive challenge model, compensatory mechanism, healthy volunteers, hypoxia.
Abstract: The early assessment of new symptomatic drugs against Alzheimer’s disease remains difficult because of the lack of a predictive end-point. The use of a battery including different parameters could improve this early development. In order to test the reverse effect of symptomatic drugs in healthy volunteers, scientists have developed new experimental paradigms to artificially induce transient cognitive impairments in healthy volunteers akin to those observed in Alzheimer’s disease, i.e. Cognitive Challenge Models. In this context, transient hypoxia could be a relevant Cognitive Challenge Model. The deleterious effects of hypoxia on cognition, as described in the literature, should be considered carefully since they are usually assessed with different populations that do not have the same hypoxic sensitivity. Hypoxia can be obtained by the means of two different methods: normobaric and hypobaric hypoxia. In both designs, cognitive changes can be directly modulated by the severity of hypoxic levels. The purpose of this review is to gather existing support on the application of hypoxia within different cognitive domains and to highlight the scientific interests of such a model to predict and select promising drug candidates. We aimed at reviewing in detail the methods, designs and cognitive paradigms used in non-pharmacological hypoxia studies. Probing the four main cognitive functions will allow identifying the extent to which different hypoxia designs selectively compromise cognitive functioning. For each cognitive process, the convergent and divergent results are discussed in terms of paradigm differences whereas we will focus on defining the optimal methodology for obtaining the desired effects.
Export Options
About this article
Cite this article as:
Lanteaume Laura, Cassé-Perrot Catherine, Lefebvre Marie-Noëlle, Audebert Christine, Deguil Julie, Auffret Alexandra, Otten Lisa, Bartrés-Faz David, Blin Olivier, Bordet Régis and Micallef Joëlle, Neurobehavioral and Cognitive Changes Induced by Hypoxia in Healthy Volunteers, CNS & Neurological Disorders - Drug Targets 2016; 15 (7) . https://dx.doi.org/10.2174/1871527315666160518125612
DOI https://dx.doi.org/10.2174/1871527315666160518125612 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Current Pharmaceutical Design Current Management of Chordoma
Current Drug Therapy Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Autism - A Comprehensive Array of Prominent Signs and Symptoms
Current Pharmaceutical Design Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design WNT4 Signaling in Female Gonadal Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets An Overview on the Search for Schizophrenia Biomarkers
CNS & Neurological Disorders - Drug Targets Proceedings of the Regional Conference of the International Society for Adolescent Psychiatry and Psychology (ISAPP), a Joint Conference with 18<sup>th</sup> National Symposium of Adolescent Mental Health, Ankara, Turkey, November 21-24, 2013<sup>1</sup>
Adolescent Psychiatry Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Serotonin 5-HT<sub>1A</sub> Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Current Pharmaceutical Design Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry The Impact of Marijuana Use on Memory in HIV-Infected Patients: A Comprehensive Review of the HIV and Marijuana Literatures
Current Drug Abuse Reviews Targeting the Cholinergic System for Neuroprotection and/or Enhancement of Functional Recovery Following Neurotrauma
Current Pharmaceutical Design Sex, Stress and their Influence on Respiratory Regulation
Current Pharmaceutical Design